浏览全部资源
扫码关注微信
1.上海中医药大学附属市中医医院肿瘤临床医学中心/上海市中医医院肿瘤研究所(上海 200071)
2.上海中医药大学附属普陀医院结核病科(上海 200062)
李佳轩,女,硕士研究生,主要从事中医药防治肿瘤的临床与基础研究工作
田建辉,主任医师,教授,博士研究生导师; E-mail:tjhhawk@shutcm.edu.cn
纸质出版日期:2024-12-10,
收稿日期:2024-06-30,
移动端阅览
李佳轩,罗斌,冯茜,等.田建辉治疗恶性肿瘤及其合并症常用药对⁃药组撷菁[J].上海中医药杂志,2024,58(12):95-99.
LI Jiaxuan,LUO Bin,FENG Qian,et al.Tian Jianhui's commonly used herb pairs and herb groups in treating malignant tumors and their comorbidities[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(12):95-99.
李佳轩,罗斌,冯茜,等.田建辉治疗恶性肿瘤及其合并症常用药对⁃药组撷菁[J].上海中医药杂志,2024,58(12):95-99. DOI: 10.16305/j.1007-1334.2024.z20240630005.
LI Jiaxuan,LUO Bin,FENG Qian,et al.Tian Jianhui's commonly used herb pairs and herb groups in treating malignant tumors and their comorbidities[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(12):95-99. DOI: 10.16305/j.1007-1334.2024.z20240630005.
介绍田建辉教授治疗恶性肿瘤及其合并症的常用药对-药组,探讨其组方思路及用药特色。认为恶性肿瘤核心病机为正虚伏毒、神机失用,临证强调扶正治癌、形神并调的重要性,形成“扶正治癌”药组、“调神治癌”药组、“蠲毒抑癌”药组;提出恶性肿瘤本身与其并发(病)症之间存在共性病机,主张以证统病,病证结合,随症加减,从而形成治疗恶性肿瘤相关性疾病核心药组。
This article introduces the commonly used herb pairs and herb groups by Professor Tian Jianhui in the treatment of malignant tumors and their comorbidities, and discusses his approach to formulation and unique characteristics in medication use. Professor Tian identifies the core pathogenesis of malignant tumors as vital qi deficiency and latent toxins as well as malfunction of the spirit mechanism. His clinical practice emphasizes the importance of supporting the body's vital qi to treat cancer and balancing the form and spirit. He has developed three main herb groups: "Fuzheng Zhiai (strengthening vital qi to treat cancer)" group, "Tiaoshen Zhiai (regulating the spirit to treat cancer)" group, and "Juandu Yiai (detoxifying and suppressing cancer)" group. Additionally, he proposes that malignant tumors and their comorbidities share common pathogenesis. Therefore, he advocates to integrate comorbidities through syndrome differentiation, combine disease diagnosis with syndrome differentiation, and adjust treatment based on symptoms, thereby forming core herb groups for treating malignancy-related diseases.
恶性肿瘤药对药组临床应用中医药疗法
malignant tumorsherb pairsherb groupsclinical applicationtraditional Chinese medicine therapy
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
WANG C, ZENG Q, GÜL Z M, et al. Circadian tumor infiltration and function of CD8+T cells dictate immunotherapy efficacy[J]. Cell, 2024, 187(11): 2690-2702.
SWANTON C, BERNARD E, ABBOSH C, et al. Embracing cancer complexity:Hallmarks of systemic disease[J]. Cell, 2024, 187(7): 1589-1616.
CHEN A C Y, JAISWAL S, MARTINEZ D, et al. The aged tumor microenvironment limits T cell control of cancer[J]. Nat Immunol, 2024, 25(6): 1033-1045.
ECKERLING A, RICON-BECKER I, SORSKI L, et al. Stress and cancer:mechanisms, significance and future directions[J]. Nat Rev Cancer, 2021, 21(12): 767-785.
中华中医药学会血液病分会,中国民族医药学会血液病分会,中国中西医结合学会肿瘤专业委员会,等. 恶性肿瘤中医维持治疗专家共识[J]. 北京中医药大学学报, 2024, 47(1): 141-148.
田建辉,刘海涛,董昌盛,等. 御神在肿瘤防治中的作用探析[J]. 中医杂志, 2018, 59(24): 2093-2098.
刘海涛,田建辉,刘嘉湘. 调神防治癌症八法[J]. 中华中医药杂志, 2019, 34(5): 2270-2273.
臧文华,卞华,白红霞,等. 术语“药对”源流考[J]. 中国中医基础医学杂志, 2020, 26(5): 571-574.
张艺,王庆国,刘男男,等. 从《神农本草经》谈张仲景运用附子的证治特色[J]. 中华中医药杂志, 2022, 37(4): 1970-1973.
季文达,马骏,肖正,等. “诸病通用药”的体例构建及辨治模式探析[J]. 南京中医药大学学报, 2024, 40(1): 13-17.
王振兴,潘怡,张秀,等. 邓中甲治疗肝系病证常用药组选析[J]. 辽宁中医杂志, 2017, 44(7): 1377-1379.
张孝刚,胡帅航,田培裕,等. 朴炳奎治疗肿瘤常用药组探析[J]. 中医杂志, 2021, 62(16): 1395-1399.
刘嘉湘,田建辉. 传承中医药学术精华,促进肿瘤学创新发展[J]. 上海中医药杂志, 2020, 54(7): 29-33.
田建辉,刘海涛. “通”以治癌[J]. 上海中医药杂志, 2018, 52(8): 5-8, 17.
田建辉. 传承《黄帝内经》重“神”思想,倡导“调神治癌”——上海中医药大学附属市中医医院田建辉研究团队“调神治癌”概述[J]. 世界科学技术-中医药现代化, 2023, 25(5): 1517-1524.
田建辉. “正虚伏毒”为肺癌发病的核心病机[J]. 上海中医药杂志, 2016, 50(12): 10-14.
田建辉,刘嘉湘. 刘嘉湘恶性肿瘤攻邪法度探讨[J]. 中医杂志, 2017, 58(2): 104-107.
杨美清,刘海涛,杨蕴,等. 基于数据挖掘的田建辉治疗妇科癌用药规律研究[J]. 上海中医药杂志, 2020, 54(5): 61-65.
张龙,刘海涛,田建辉. “五脏元真通畅”与“通以治癌”[J]. 上海中医药杂志, 2023, 57(4): 13-17.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构